1,3-diethyl-2-oxo-2,3-dihydro-1H-benzoimidazole-5-carboxylic acid | 14624-86-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1,3-diethyl-2-oxo-2,3-dihydro-1H-benzoimidazole-5-carboxylic acid
• 英文别名: 1,3-Diethyl-2-oxo-2,3-dihydro-1H-benzoimidazole-5-carboxylic acid；1,3-diethyl-2-oxobenzimidazole-5-carboxylic acid
• CAS: 14624-86-3
• 化学式: C₁₂H₁₄N₂O₃
• mdl: MFCD07402411
• 分子量: 234.255
• InChiKey: AXWFSVGZVPJGKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  60.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  1,3-diethyl-2-oxo-2,3-dihydro-1H-benzoimidazole-5-carboxylic acid 在 copper diacetate 、 草酰氯 、 ammonium acetate 、 溴 、 溶剂黄146 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 19.5h， 生成 1,3-diethyl-5-(5-m-tolyl-3H-imidazol-4-yl)-1,3-dihydro-benzoimidazol-2-one
  参考文献：
  名称：

  Benzimidazolone p38 inhibitors

  摘要：

  The synthesis and in vitro p38alpha activity of a novel series of benzimidazolone inhibitors is described. The p38alpha SAR is consistent with a mode of binding wherein the benzimidazolone carbonyl serves as the H-bond acceptor to Met109 of p38alpha in a manner analogous to the pyridine nitrogen of prototypical pyridylimidazole p38 inhibitors. Potent p38alpha activity comparable to that of several previously reported p38 inhibitors is observed for this novel chemotype. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.023
• 作为产物：
  描述：

  2-氧-2,3-二氢-1H-苯并咪唑-5-羧酸 在 lithium hydroxide 、 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 1,3-diethyl-2-oxo-2,3-dihydro-1H-benzoimidazole-5-carboxylic acid
  参考文献：
  名称：

  Benzimidazolone p38 inhibitors

  摘要：

  The synthesis and in vitro p38alpha activity of a novel series of benzimidazolone inhibitors is described. The p38alpha SAR is consistent with a mode of binding wherein the benzimidazolone carbonyl serves as the H-bond acceptor to Met109 of p38alpha in a manner analogous to the pyridine nitrogen of prototypical pyridylimidazole p38 inhibitors. Potent p38alpha activity comparable to that of several previously reported p38 inhibitors is observed for this novel chemotype. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.023

文献信息

• Synthesis and bioevaluation of pyrazole-benzimidazolone hybrids as novel human 4-Hydroxyphenylpyruvate dioxygenase inhibitors
  作者：Yu-Ling Xu、Hong-Yan Lin、Xu Ruan、Sheng-Gang Yang、Ge-Fei Hao、Wen-Chao Yang、Guang-Fu Yang

  DOI：10.1016/j.ejmech.2015.01.018

  日期：2015.3

  4-Hydroxyphenylpyruvate dioxygenase (HPPD), an essential enzyme in tyrosine catabolism, is an important target for treating type I tyrosinemia. Inhibition of HPPD can effectively alleviate the symptoms of type I tyrosinemia. However, only one commercial HPPD inhibitor, 2-(2-nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione (NTBC), has been available for clinical use so far. In the present study, a series of novel pyrazole-benzimidazolone hybrids were designed, synthesized and evaluated as potent human HPPD inhibitors. Most of the new compounds displayed significant inhibitory activity against the recombinant human HPPD. Moreover, compound 91 was identified as the most potent candidate with IC50 value of 0.021 mu M against recombinant human HPPD, about 3-fold more potent than NTBC. Thus the pyrazole-benzimidazolone hybrid has great potential to be further developed for the treatment of type I tyrosinemia. (C) 2015 Elsevier Masson SAS. All rights reserved.
• BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS
  申请人：Pfizer Products Inc.

  公开号：EP1370557B1

  公开（公告）日：2005-11-16
• Benzimidazolone p38 inhibitors
  作者：Mark A. Dombroski、Michael A. Letavic、Kim F. McClure、John T. Barberia、Thomas J. Carty、Santo R. Cortina、Csilla Csiki、Alan J. Dipesa、Nancy C. Elliott、Christopher A. Gabel、Crystal K. Jordan、Jeff M. Labasi、William H. Martin、Kevin M. Peese、Ingrid A. Stock、Linne Svensson、Francis J. Sweeney、Chul H. Yu

  DOI：10.1016/j.bmcl.2003.12.023

  日期：2004.2

  The synthesis and in vitro p38alpha activity of a novel series of benzimidazolone inhibitors is described. The p38alpha SAR is consistent with a mode of binding wherein the benzimidazolone carbonyl serves as the H-bond acceptor to Met109 of p38alpha in a manner analogous to the pyridine nitrogen of prototypical pyridylimidazole p38 inhibitors. Potent p38alpha activity comparable to that of several previously reported p38 inhibitors is observed for this novel chemotype. (C) 2003 Elsevier Ltd. All rights reserved.